PBAE-coated AdNuPARmE1A: Overcoming oncolytic virotherapy hurdles

P. Brugada-Vila; M. Rovira-Rigau; C. Castells-Sala; A. Cascante; S. Borros; C. Fillat

doi:10.1089/hum.2017.29055.abstracts

PBAE-coated AdNuPARmE1A: Overcoming oncolytic virotherapy hurdles

P. Brugada-Vila, M. Rovira-Rigau, C. Castells-Sala, A. Cascante, S. Borros, C. Fillat

Producció científica: Article en revista indexada › Resum de jornada › Avaluat per experts

Idioma original	Anglès
Pàgines (de-a)	A25-A26
Nombre de pàgines	2
Revista	Human Gene Therapy
Volum	28
Número	12
DOIs	https://doi.org/10.1089/hum.2017.29055.abstracts
Estat de la publicació	Publicada - de des. 2017
Esdeveniment	European Society of Gene and Cell Therapy (ESCGT) Congress - Berlin, Germany Durada: 17 d’oct. 2017 → 20 d’oct. 2017

Accés al document

10.1089/hum.2017.29055.abstracts

Altres arxius i enllaços

Enllaç a la publicació de WoS

Com citar-ho

@article{0090839ae99246d7b313f733355e2b07,

title = "PBAE-coated AdNuPARmE1A: Overcoming oncolytic virotherapy hurdles",

author = "P. Brugada-Vila and M. Rovira-Rigau and C. Castells-Sala and A. Cascante and S. Borros and C. Fillat",

year = "2017",

month = dec,

doi = "10.1089/hum.2017.29055.abstracts",

language = "English",

volume = "28",

pages = "A25--A26",

journal = "Human Gene Therapy",

issn = "1043-0342",

publisher = "Raz{\'o}n y Fe",

number = "12",

note = "European Society of Gene and Cell Therapy (ESCGT) Congress ; Conference date: 17-10-2017 Through 20-10-2017",

}

TY - JOUR

T1 - PBAE-coated AdNuPARmE1A

T2 - European Society of Gene and Cell Therapy (ESCGT) Congress

AU - Brugada-Vila, P.

AU - Rovira-Rigau, M.

AU - Castells-Sala, C.

AU - Cascante, A.

AU - Borros, S.

AU - Fillat, C.

PY - 2017/12

Y1 - 2017/12

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=pure_univeritat_ramon_llull&SrcAuth=WosAPI&KeyUT=WOS:000418410700072&DestLinkType=FullRecord&DestApp=WOS_CPL

U2 - 10.1089/hum.2017.29055.abstracts

DO - 10.1089/hum.2017.29055.abstracts

M3 - Meeting Abstract

SN - 1043-0342

VL - 28

SP - A25-A26

JO - Human Gene Therapy

JF - Human Gene Therapy

IS - 12

Y2 - 17 October 2017 through 20 October 2017

ER -